عرض بسيط للتسجيلة

المؤلفSamaha, Ali A.
المؤلفMouawia, Hussein
المؤلفFawaz, Mirna
المؤلفHassan, Hamad
المؤلفSalami, Ali
المؤلفBazzal, Ali A.
المؤلفSaab, Hamid B.
المؤلفAl-Wakeel, Mohamed
المؤلفAlsaabi, Ahmad
المؤلفChouman, Mohamad
المؤلفMoussawi, Mahmoud A.
المؤلفAyoub, Hassan
المؤلفRaad, Ali
المؤلفHajjeh, Ola
المؤلفEid, Ali H.
المؤلفRaad, Houssam
تاريخ الإتاحة2023-09-25T10:26:16Z
تاريخ النشر2021
اسم المنشورViruses
المصدرScopus
معرّف المصادر الموحدhttp://dx.doi.org/10.3390/v13060989
معرّف المصادر الموحدhttp://hdl.handle.net/10576/47953
الملخصObjective: This study was designed to determine the efficacy of ivermectin, an FDA-approved drug, in producing clinical benefits and decreasing the viral load of SARS-CoV-2 among asymptomatic subjects that tested positive for this virus in Lebanon. Methods: A randomized controlled trial was conducted in 100 asymptomatic Lebanese subjects that have tested positive for SARS-CoV2. Fifty patients received standard preventive treatment, mainly supplements, and the experimental group received a single dose (according to body weight) of ivermectin, in addition to the same supplements the control group received. Results: There was no significant difference (p = 0.06) between Ct-values of the two groups before the regimen was started (day zero), indicating that subjects in both groups had similar viral loads. At 72 h after the regimen started, the increase in Ct-values was dramatically higher in the ivermectin than in the control group. In the ivermectin group, Ct increased from 15.13 ± 2.07 (day zero) to 30.14 ± 6.22 (day three; mean ± SD), compared to the control group, where the Ct values increased only from 14.20 ± 2.48 (day zero) to 18.96 ± 3.26 (day three; mean ± SD). Moreover, more subjects in the control group developed clinical symptoms. Three individuals (6%) required hospitalization, compared to the ivermectin group (0%). Conclusion: Ivermectin appears to be efficacious in providing clinical benefits in a randomized treatment of asymptomatic SARS-CoV-2-positive subjects, effectively resulting in fewer symptoms, lower viral load and reduced hospital admissions. However, larger-scale trials are warranted for this conclusion to be further cemented.
اللغةen
الناشرMDPI
الموضوعClinical trial
COVID-19
Ivermectin
Lebanon
Pandemic
SARS-CoV-2
Therapy
العنوانEffects of a single dose of ivermectin on viral and clinical outcomes in asymptomatic sars-cov-2 infected subjects: A pilot clinical trial in lebanon
النوعArticle
رقم العدد6
رقم المجلد13
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة